Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Jiuzhou Pharmaceutical, including stock price movements and trading volumes [1][2] - As of September 29, Jiuzhou Pharmaceutical's stock price increased by 2.06%, reaching 19.32 CNY per share, with a total market capitalization of 17.184 billion CNY [1] - The company has seen a year-to-date stock price increase of 46.52%, with a 1.68% rise over the last five trading days and a 28.87% increase over the last 60 days [1] Group 2 - Jiuzhou Pharmaceutical's main business revenue composition includes 79.81% from new drug custom development and production services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] - For the first half of 2025, Jiuzhou Pharmaceutical reported a revenue of 2.871 billion CNY, reflecting a year-on-year growth of 3.86%, and a net profit attributable to shareholders of 526 million CNY, up 10.70% [2][3] - The company has distributed a total of 2.183 billion CNY in dividends since its A-share listing, with 1.245 billion CNY distributed in the last three years [3]
九洲药业涨2.06%,成交额3.25亿元,主力资金净流入148.81万元